Texas Yale Capital Corp. Sells 1,605 Shares of Novo Nordisk A/S (NYSE:NVO)

Texas Yale Capital Corp. reduced its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 4.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 33,221 shares of the company’s stock after selling 1,605 shares during the quarter. Texas Yale Capital Corp.’s holdings in Novo Nordisk A/S were worth $2,858,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in NVO. Bank of Nova Scotia lifted its position in Novo Nordisk A/S by 62.5% during the 4th quarter. Bank of Nova Scotia now owns 12,650 shares of the company’s stock valued at $1,092,000 after acquiring an additional 4,866 shares during the period. Renaissance Technologies LLC grew its holdings in Novo Nordisk A/S by 1.5% during the fourth quarter. Renaissance Technologies LLC now owns 8,312,996 shares of the company’s stock valued at $715,084,000 after purchasing an additional 123,681 shares during the period. Employees Retirement System of Texas lifted its holdings in Novo Nordisk A/S by 9.9% during the fourth quarter. Employees Retirement System of Texas now owns 72,964 shares of the company’s stock valued at $6,276,000 after purchasing an additional 6,560 shares in the last quarter. Bank of Montreal Can lifted its holdings in shares of Novo Nordisk A/S by 53.7% in the fourth quarter. Bank of Montreal Can now owns 1,722,937 shares of the company’s stock worth $148,207,000 after buying an additional 601,845 shares in the last quarter. Finally, Trek Financial LLC bought a new position in shares of Novo Nordisk A/S during the 4th quarter valued at about $212,000. 11.54% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the stock. Stifel Nicolaus downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday, March 3rd. UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. BMO Capital Markets dropped their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. Kepler Capital Markets upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Thursday, March 13th. Finally, Morgan Stanley initiated coverage on shares of Novo Nordisk A/S in a research note on Wednesday, February 12th. They set an “equal weight” rating for the company. Three research analysts have rated the stock with a hold rating, six have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $145.25.

Novo Nordisk A/S Price Performance

NVO stock opened at $61.41 on Wednesday. The business’s fifty day moving average price is $79.45 and its 200 day moving average price is $95.04. Novo Nordisk A/S has a 12-month low of $60.11 and a 12-month high of $148.15. The company has a market capitalization of $275.60 billion, a PE ratio of 18.67, a P/E/G ratio of 0.90 and a beta of 0.61. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. On average, sell-side analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The company also recently disclosed a semi-annual dividend, which was paid on Tuesday, April 8th. Investors of record on Monday, March 31st were given a $0.7874 dividend. The ex-dividend date was Monday, March 31st. This represents a yield of 1.2%. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 49.54%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.